The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： T K,Sahin

第一单位： Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Electronic address: takorsah@gmail.com.

作者： T K,Sahin ^[1] ; A,Isik ^[2] ; D C,Guven ^[3] ; F,Ceylan ^[4] ; B,Babaoglu ^[5] ; A,Akyol ^[6] ; S,Yalcin ^[3] ; O,Dizdar ^[7]

作者单位： Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Electronic address: takorsah@gmail.com. ^[1] Hacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, Ankara, Turkey. ^[2] Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. ^[3] Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey. ^[4] Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey. ^[5] Hacettepe University Transgenic Animal Technologies Research and Application Center, Sıhhiye, Ankara, Turkey; Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey. ^[6] Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. Electronic address: dromerdizdar@gmail.com. ^[7]

关键词 Class III β-tubulin (TUBB3)FOLFIRINOX Gemcitabine and nabpaclitaxel (GnP)Pancreatic cancer The human equilibrative nucleoside transporter 1 (hENT1)